Bevacizumab intravitreo como tratamiento de las telangiectasias yuxtafoveales idiopaticas tipo i

Clinical case We report a case of a 42 year-old male with a macular edema due to idiopathic juxtafoveal retinal telangiectasis type i , treated with 3 sequential injections of intravitreal bevacizumab (1.25 mg in 0.05 ml). Anatomical improvements were observed after one year of follow up. Discussion There is currently no general consensus regarding the treatment of unilateral idiopathic juxtafoveal telangiectasis. The therapeutic options are, grid laser photocoagulation, intravitreal triamcinolone, verteporfin photodynamic therapy, or anti-VEGF. Visual acuity and anatomical improvements were observed in this case after intravitreal bevacizumab. Thus, intravitreal bevacizumab seems to be effective to treat macular edema in idiopathic juxtafoveal telangiectasis type i .